Effect of grafting BMP2-derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 8, Issue 1, 2014, Pages 15-28

  Mercado, Angel E ^a   Yang, Xiaoming ^b   He, Xuezhong ^a   Jabbari, Esmaiel ^a  

^a University of South Carolina   (United States)

^b Dorn Research Institute   (United States)

Author keywords

Bone morphogenetic peptide; Gene expression; Grafting; Marrow stromal cells; Nanoparticles; Osteogenesis

Indexed keywords

AMINO ACIDS; BIODEGRADABLE POLYMERS; BONE; CELL MEMBRANES; CELL SIGNALING; CYTOLOGY; ETHYLENE; GRAFTING (CHEMICAL); PEPTIDES; STEM CELLS; TRANSCRIPTION;

BONE MORPHOGENETIC PEPTIDE; BONE MORPHOGENETIC PROTEIN-2; CELL SURFACE RECEPTORS; GENES EXPRESSION; MARROW STROMAL CELL; MORPHOGENETICS; OSTEOGENESIS; OSTEOGENIC; PEPTIDE PROTEINS; STRONG INTERACTION;

NANOPARTICLES;

BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CD31 ANTIGEN; CYSTEINE; MESSENGER RNA; NANOPARTICLE; OSTEOCALCIN; OSTEOPONTIN; POLYLACTIDE; POLYLACTIDE CO ETHYLENE OXIDE FUMARATE; POLYLACTIDE FUMARATE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SULFIDE; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN 2 NANOPARTICLE; POLY(LACTIDE CO ETHYLENE FUMARATE); POLY(LACTIDE FUMARATE); POLYMER;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BONE DEVELOPMENT; BONE MINERALIZATION; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; DRUG MEGADOSE; GENE EXPRESSION; MALE; NONHUMAN; PEPTIDE SYNTHESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; STROMA CELL; BONE MARROW STROMA CELL; CELL CULTURE; CELL ISOLATION; DRUG MECHANISM; DRUG SYNTHESIS;

BONE MORPHOGENETIC PEPTIDE; GENE EXPRESSION; GRAFTING; MARROW STROMAL CELLS; NANOPARTICLES; OSTEOGENESIS;

BASE SEQUENCE; BIOLOGICAL MARKERS; BLOOD VESSELS; BONE MORPHOGENETIC PROTEIN 2; DNA PRIMERS; HUMANS; NANOPARTICLES; OSTEOGENESIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84891635564     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1487     Document Type: Article

References (74)

1. Attisano L, Silvestri C, Izzi L, et al. 2001; The transcriptional role of Smads and FAST (FoxH1) in TGFβ and activin signalling. Mol Cell Endocrinol 180: 3-11.
2. Aubin JE, Liu F, Malaval L, et al. 1995; Osteoblast and chondroblast differentiation. Bone 17: 77-83S.
3. Bae SC, Lee YH. 2006; Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 366: 58-66.
4. Behnam K, Phillips ML, Silva JD, et al. 2005; BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein. J Orthop Res 23: 175-180.
5. Caestecker MD. 2004; The transforming growth factor-β superfamily of receptors. Cyto Grow Fact Rev 15: 1-11.
6. Cao X, Chen D. 2005; The BMP signaling and in vivo bone formation. Gene 357: 1-8.
7. Centrella M, Christakos S, McCarthy TL. 2004; Skeletal hormones and the C/EBP and Runx transcription factors: interactions that integrate and redefine gene expression. Gene 342: 13-24.
8. Chen FM, Wu ZF, Sun HH, et al. 2006; Release of bioactive BMP from dextran-derived microspheres: a novel delivery concept. Int J Pharm 307: 23-32.
9. Chen FM, Zhao YM, Sun HH, et al. 2007; Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: formulation and characteristics. J Control Release 118: 65-77.
10. Chung Y-I, Ahn K-M, Jeon S-H, et al. 2007; Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release 121: 91-99.
11. Ciarmela P, Wiater E, Smith SM, et al. 2009; Presence, actions, and regulation of myostatin in rat uterus and myometrial cells. Endocrinology 150: 906-914.
12. Drissi H, Luc Q, Shakoori R, et al. 2000; Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J Cell Physiol 184: 341-350.
13. Facer SR, Zaharias RS, Andracki ME, et al. 2005; Rotary culture enhances pre-osteoblast aggregation and mineralization. J Dent Res 84: 542-547.
14. Foster KA, Yazdanian M, Audus KL. 2001; Microparticulate uptake mechanisms of in vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol 53: 57-66.
15. Fu YC, Nie H, Ho ML, et al. 2008; Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng 99: 996-1006.
16. Gabet Y, Muller R, Regev E, et al. 2004; Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone 35: 65-73.
17. Grunsven LAV, Verstappen G, Huylebroeck D, et al. 2005; Smads and chromatin modulation. Cytokine Growth F•• R• 16: 495-512.
18. Hamada Y, Egusa H, Kaneda Y, et al. 2007; Synthetic osteopontin-derived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials. Dent Mater J 26: 487-492.
19. Hartung A, Bitton-Worms K, Rechtman MM, et al. 2006; Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol 26: 7791-7805.
20. Hassan MQ, Tare RS, Lee SH, et al. 2006; BMP2 Commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. J Biol Chem 281: 40515-40526.
21. He X, Jabbari E. 2007; Material properties and cytocompatibility of injectable MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for marrow stromal cells. Biomacromolecules 8: 780-792.
22. He X, Jabbari E. 2008; Synthesis and characterization of bioresorbable in situ crosslinkable ultra-low molecular weight poly(lactide) macromer. J Mater Sci Mater Med 19: 311-318.
23. He X, Ma J, Jabbari E. 2008; Effect of grafting RGD and BMP-2 protein-derived peptides to a hydrogel substrate on osteogenic differentiation of marrow stromal cells. Langmuir 24: 12508-12516.
24. He X, Ma J, Jabbari E. 2010; Migration of marrow stromal cells in response to sustained release of stromal-derived factor-1α from poly(lactide ethylene oxide fumarate) hydrogels. Int J Pharm 390: 107-116.
25. He X, Ma J, Mercado AE, et al. 2008; Cytotoxicity of paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Pharm Res 25: 1552-1562.
26. Henderson JA, He X, Jabbari E. 2008; Concurrent differentiation of marrow stromal cells to osteogenic and vasculogenic lineages. Macromol Biosci 8: 499-507.
27. Hillger F, Herr G, Rudolph R, et al. 2005; Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 280: 14974-14980.
28. Hu Z, Peel SA, Ho SK, et al. 2005; Role of bovine bone morphogenetic proteins in bone matrix protein and osteoblast-related gene expression during rat bone marrow stromal cell differentiation. J Craniofac Surg 16: 1006-1014.
29. Huss R, Hoy CA, Deeg HJ. 1995; Contact- and growth factor-dependent survival in a canine marrow-derived stromal cell line. Blood 85: 2414-2421.
30. Jabbari E, He X, Valarmathi M, et al. 2009; Material properties and bone marrow stromal cells response to in situ crosslinkable RGD-functionlized lactide-co-glycolide scaffolds. J Biomed Mater Res A 89: 124-137.
31. Jimi E, Hirata S, Shin M, et al. 2010; Molecular mechanisms of BMP-induced bone formation: Cross-talk between BMP and NF-κB signaling pathways in osteoblastogenesis. Jpn Dent Sci Rev 46: 33-42.
32. Jones AL, Bucholz RW, Bosse MJ, et al. 2006; Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88: 1431-1441.
33. Kaiser E, Colescott RL, Bossinger CD, et al. 1970; Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 34: 595-598.
34. Kleeff J, Maruyama H, Ishiwata T, et al. 1999; Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 1202-1216.
35. Langenfeld EM, Langenfeld J. 2004; Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2: 141-149.
36. Langenfeld EM, Calvano SE, Abou-Nukta F, et al. 2003; The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454.
37. Laub M, Seul T, Schmachtenberg E, et al. 2001; Molecular modelling of bone morphogenetic protein-2 (BMP-2) by 3D-rapid prototyping. Materialwiss Werkstofftech 32: 926-930.
38. Leali D, Dell'Era P, Stabile H, et al. 2003; Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171: 1085-1093.
39. Lee SH, Shin H. 2007; Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 59: 339-59.
40. Lee M-H, Kim Y-J, Kim H-J, et al. 2003a; BMP-2-induced Runx2 expression is mediated by Dlx5, and TGFβ opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278: 34387-34394.
41. Lee K-S, Kim H-J, Li Q-L, et al. 2000; Runx2 is a common target of transforming growth factor-β1 and bone morphogenetic protein-2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20: 8783-8792.
42. Lee M-H, Kwon T-G, Park H-S, et al. 2003b; BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 309: 689-694.
43. Lin H, Zhao Y, Sun W, et al. 2008; The effect of crosslinking heparin to demineralized bone matrix on mechanical strength and specific binding to human bone morphogenetic protein-2. Biomaterials 29: 1189-1197.
44. Lisi S, Peterkova R, Peterka M, et al. 2003; Tooth morphogenesis and pattern of odontoblast differentiation. Connect Tissue Res 44(suppl 1): 167-170.
45. Liu HW, Chen CH, Tsai CL, et al. 2006; Targeted delivery system for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation. Bone 39: 825-836.
46. Mauney JR, Blumberg J, Pirun M, et al. 2004; Osteogenic differentiation of human bone marrow stromal cells on partially demineralized bone scaffolds in vitro. Tissue Eng 10: 81-92.
47. McKay B, Sandhu HS. 2002; Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 27: S66-85.
48. Mercado AE, He XZ, Xu WJ, et al. 2008; The release characteristics of a model protein from self-assembled succinimide-terminated poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Nanotechnology 19: 325609.
49. Mercado AE, Ma J, He X, et al. 2009; Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles. J Control Release 140: 148-156.
50. Nadri S, Soleimani M, Hosseni RH, et al. 2007; An efficient method for isolation of murine bone marrow mesenchymal stem cells. Int J Dev Biol 51: 723-729.
51. Owen TA, Aronow M, Shalhoub V, et al. 1990; Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143: 420-430.
52. Perez VAD, Ali Z, Alastalo TP, et al. 2011; BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell Biol 192: 171-188.
53. Pfaffl MW. 2001; A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
54. Rai B, Teoh SH, Ho KH, et al. 2004; The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds. Biomaterials 25: 5499-5506.
55. Raida M, Clement JH, Leek RD, et al. 2005; Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol 131: 741-750.
56. Redhead HM, Davis SS, Illum L. 2001; Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release 70: 353-363.
57. Ripamonti U, Reddi AH. 1997; Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. Crit Rev Oral Biol Med 8: 154-163.
58. Risau W, Flamme I. 1995; Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91.
59. Ross S, Hill CS. 2008; How the Smads regulate transcription. Int J Biochem Cell B 40: 383-408.
60. Rossi EA, Sharkey RM, McBride W, et al. 2003; Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 9: 3886-3896S.
61. Sahoo SK, Panyam J, Prabha S, et al. 2002; Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82: 105-114.
62. Saito A, Suzuki Y, Ogata S-I, et al. 2004; Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. J Biomed Mater Res A 70: 115-121.
63. Saito A, Suzuki Y, Ogata S-i, et al. 2003; Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim Biophys Acta 1651: 60-67.
64. Shi X, Wang Y, Varshney RR, et al. 2010; Microsphere-based drug releasing scaffolds for inducing osteogenesis of human mesenchymal stem cells in vitro. Eur J Pharm Sci 39: 59-67.
65. Shields LBE, Raque GH, Glassman SD, et al. 2006; Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31: 542-547.
66. Sieber C, Kopf J, Hiepen C, et al. 2009; Recent advances in BMP receptor signaling. Cyto Grow Fact Rev 20: 343-355.
67. Vehof JWM, Ruijter AED, Spauwen PHM, et al. 2001; Influence of rhBMP-2 on rat bone marrow stromal cells cultured on titanium fiber mesh. Tissue Eng 7: 373-383.
68. Wei G, Jin Q, Giannobile WV, et al. 2007; The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 28: 2087-2096.
69. Wozney JM. 2002; Overview of bone morphogenetic proteins. Spine 27: S2-8.
70. Xie JW, Wang CH. 2005; Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm Res 22: 2079-2090.
71. Yamagiwa H, Endo N, Tokunaga K, et al. 2001; In vivo bone-forming capacity of human bone marrow-derived stromal cells is stimulated by recombinant human bone morphogenetic protein-2. J Bone Miner Metab 19: 20-28.
72. Yang HS, La W-G, Bhang SH, et al. 2010; Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 16: 1225-1233.
73. Yang ZJ, Yuan H, Zou P, et al. 1997; Osteogenic responses to extraskeletally implanted synthetic porous calcium phosphate ceramics: an early stage histomorphological study in dogs. J Mater Sci Mater Med 8: 697-701.
74. Yasko AW, Lane JM, Fellinger EJ, et al. 1992; The healing of segmental bone defects induced by recombinant human bone morphogenetic protein (rhBMP-2). J Bone Jt Surg Am 74: 659-670.